Impact of Day 14 Peripheral Blood Chimerism after Allogeneic Hematopoietic Stem Cell Bone Transplantation on the Treatment Outcome of Non-Malignant Disease

다국어 초록 (Multilingual Abstract)

Background: The impact of early peripheral blood chimerism on the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is unclear. We aimed to determine whether day 14 peripheral blood chimerism after allo-HSCT predicts outcomes in patients with non-malignant diseases.
Methods: Data from 56 patients who received allo-HSCT between April 2007 and March 2016 were retrospectively analyzed. Chimerism was evaluated using short-tandem repeat polymerase chain reaction, with mixed chimerism (MC) defined as greater than 1% recipient cells which was further categorized into low-level MC (> 1% and < 15% of recipient-derived cells) and high-level MC (≥ 15% of the recipient-derived cells).
Results: Thirty-six patients showed complete donor chimerism (CC), 14 low-level MC, and 6 high-level MC at day 14 post-transplant. The estimated 5-year event-free survival (EFS) was higher in the CC or low-level MC groups than in the high-level MC group (86.1% vs. 71.4% vs.
33.3%; P = 0.001). In BM or peripheral blood stem cell (BM/PBSC) transplants, the 5-year EFS was higher in the CC or low-level MC group than in the high-level MC group (93.1% vs. 66.7% vs. 0%; P < 0.001). However, in cord blood transplants, the 5-year OS and EFS according to the day 14 peripheral blood chimerism did not reach statistical significance.
Conclusion: Although CC is not always necessary after allo-HSCT for non-malignant diseases, our data suggest that day 14 peripheral blood chimerism may predict outcomes in patients with non-malignant diseases who underwent BM/PBSC transplants.

참고문헌 (Reference)

1 Park CH, "Underestimation of recipient DNA in bone marrow by post-transplant chimerism analyses using DNA extracted from EDTA-collected aspirate samples in pediatric acute myeloid leukemia" 41 (41): 138-143, 2011

2 Lawler M, "Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation(SCT)for severe aplastic anaemia(SAA) : indication for routine assessment of chimerism post SCT for SAA" 144 (144): 933-945, 2009

3 Bader P, "Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT" 21 (21): 487-495, 1998

4 Marsh RA, "Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation" 116 (116): 5824-5831, 2010

5 Andreani M, "Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia" 87 (87): 3494-3499, 1996

6 Willasch A, "Outcome of allogeneic stem cell transplantation in children with non-malignant diseases" 91 (91): 788-794, 2006

7 Bader P, "Monitoring of donor cell chimerism for the detection of relapse and early immunotherapeutic intervention in acute lymphoblastic leukemias" 81 (81): S25-S27, 2002

8 Oshrine BR, "Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease" 61 (61): 1852-1859, 2014

9 Dubovsky J, "Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders : implications for timely detection of engraftment, graft failure and rejection" 13 (13): 2059-, 1999

10 Ozyurek E, "Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders" 42 (42): 83-91, 2008

11 Perez-Simon JA, "Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation" 102 (102): 1108-1113, 2003

12 Gonzalez-Vicent M, "Higher doses of CD34+ PBPC are associated with a rapid acquisition of full donor chimerism and lower risk of relapse after allogeneic transplantation in pediatric patients with hematological malignancies" 33 (33): 185-189, 2011

13 Baron F, "High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation" 19 (19): 822-828, 2005

14 Ringdén O, "Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases" 39 (39): 383-388, 2007

15 Marsh RA, "Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen" 21 (21): 1460-1470, 2015

16 Antin JH, "Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation" 7 (7): 473-485, 2001

17 Rao K, "Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen" 138 (138): 1152-1160, 2016

18 Breuer S, "Early recipient chimerism testing in the T-and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation" 26 (26): 509-519, 2012

19 Ketterl TG, "Early CD3+/CD15+ peripheral blood leukocyte chimerism patterns correlate with long-term engraftment in non-malignant hematopoietic SCT" 49 (49): 572-575, 2014

20 Thiede C, "Diagnostic chimerism analysis after allogeneic stem cell transplantation : new methods and markers" 4 (4): 177-187, 2004

21 Mickelson DM, "Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT" 46 (46): 84-89, 2011

22 Hoelle W, "Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anemia" 33 (33): 219-223, 2004

23 박미림, "Clinical implications of chimerism after allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases" 대한혈액학회 46 (46): 258-264, 2011

24 Mellgren K, "Chimerism analysis in clinical practice and its relevance for the detection of graft rejection and malignant relapse in pediatric hematopoietic stem cell transplant patients" 19 (19): 758-766, 2015

25 Klein OR, "Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders" 22 (22): 895-901, 2016

26 Mussetti A, "Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or-mismatched donors" 33 (33): 347-358, 2016

27 Ringdén O, "Allogeneic hematopoietic stem cell transplantation for inherited disorders : experience in a single center" 81 (81): 718-725, 2006

28 Svenberg P, "Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism" 44 (44): 757-763, 2009

29 Parikh SH, "A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases" 20 (20): 326-336, 2014